Gene Therapy Clinical Trials
Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer
The purpose of this study is to examine the use of hypofractionated accelerated radiation therapy (HART) to treat locally advanced lung cancer. Depending on the location and size of the tumor.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- radiation: Hypofractionated accelerated radiation therapy
Eligibility
Inclusion Criteria:
- Histologically or cytologically documented malignancy of the lung including non-small
cell lung cancer or small cell lung cancer planned for definitive therapy with
fractionated radiation (60-66 Gy) and concurrent systemic therapy
- ECOG performance status of 0-2
- Age > 18 years old
- Ability to understand and the willingness to personally sign the written IRB approved
informed consent document
- Estimated life expectancy of 12 weeks or longer
Exclusion Criteria:
- Contraindication to receiving radiotherapy or systemic therapy as determined by
treating radiation and medical oncologist
- Age < 18 years old
- Tumor directly invading the major pulmonary arteries, aorta, heart or proximal
bronchial tree
- Diagnosis of interstitial pulmonary fibrosis
- Previous radiation therapy to the thorax that would result in overlapping high dose
radiation fields
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Aneesh Swamy
650-498-8495
I'm interested